Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT06200233
Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor
- NCT06200233 ↗
- Not yet recruiting
- Samsung Medical Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-label, Single-arm, Multi-center Clinical Trial of Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor
- Phase
- Phase 2
- Status
- Not yet recruiting
- Conditions
- Thymic Epithelial Tumor
- Interventions
- Rivoceranib
- Arms
- single arm · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- Objective response rate(ORR) Objective response rate(ORR)
- Sponsor
- Samsung Medical Center
- Start
- May 1, 2024 (estimated)
- Primary completion
- Mar 1, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06200233 · updated Apr 9, 2024